Aminoglycosides Market Size, Share, Industry, Forecast and outlook (2024-2031)

Aminoglycosides Market is segmented By Product Type (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin and Others), By Route of Administration (Injectables, Feed, Intra-mammary, Topical and Oral), By Application (Veterinary, Skin Infection, Respiratory diseases, UTI & Pelvic Diseases and Other Diseases), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Aminoglycosides Market Size

The global aminoglycosides market reached USD 1,636.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 2,202.2 million by 2030. The global aminoglycosides market is expected to exhibit a CAGR of 3.8% during the forecast period (2023-2030).  Due to the rising incidence of bacterial infections and the increased demand for effective antibiotics, the global aminoglycosides market is a sizable sector of the pharmaceutical industry.

The need for aminoglycoside antibiotics has been influenced by a number of factors, including a growing geriatric population, the rising prevalence of tuberculosis, the emergence of bacteria that are resistant to antibiotics, and an increasing number of hospital-acquired infections.

The rising prevalence of tuberculosis will drive the global aminoglycosides market growth, as tuberculosis (TB) is a highly contagious bacterial infection that mostly affects the lungs. For instance, according to the Centers for Disease Control and Prevention report of 2023, in 2022, there were 8,300 reported cases of tuberculosis (TB) in the United States, resulting in a rate of 2.5 cases per 100,000 people. This is a modest rise from the 7,874 cases reported in 2021. In 2022, the incidence of tuberculosis remained at 2.5 incidents per 100,000 people.

Aminoglycosides Market Scope

For know more Insights -  Download Sample

Aminoglycosides Market Dynamics

The Growing Geriatric  Population will Drive the Global Aminoglycosides Market Growth.

As the world's population ages, people' immune systems are anticipated to deteriorate, increasing their susceptibility to illness. Additionally, the chronic illnesses that older persons are more likely to have, such as diabetes, cancer, and heart disease, can raise their risk of infection. Therefore, as aminoglycosides are frequently used to treat bacterial infections in older persons, the expanding geriatric population is projected to contribute to the demand for these antibiotics.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion. Hence, owing to the above factors, the global aminoglycosides market is expected to drive over the forecast period.

The Advancements in Drug Delivery Systems will Drive the Global Aminoglycosides Market Growth

Advances in drug delivery systems are being explored in order to improve the efficacy and safety profile of aminoglycosides. Innovative drug delivery systems such as nanoparticle-based formulations, liposomal formulations, and sustained-release formulations are being developed to improve medication targeting, reduce dose frequency, and lower the risk of unwanted effects, therby driving the global aminoglycosides market over the forecast period.

For example, according to a study published in the ACS Omega journal in 2022 on the antibacterial efficacies of nanostructured aminoglycosides, the use of nanoscale drug delivery technologies, such as nanoparticles, has the potential to reduce toxicity, increase drug availability, and lower doses. Liposomes, lipids, carbohydrates, and other new nanoparticle carriers are being investigated for their ability to incorporate aminoglycosides such as kanamycin, neomycin, streptomycin, gentamicin, and amikacin. 

The Side Effects Associated with the Drugs is Hampering the Growth of the Global Aminoglycosides Market.

The potential side effects of aminoglycosides, such as kidney damage, hearing loss, and vestibular toxicity, pose substantial barriers to the global aminoglycosides market's growth. For instance, aminoglycoside-induced ototoxicity can cause chronic and severe sensorineural hearing loss, especially in high-frequency ranges, as well as acute vestibular impairment. Because these adverse effects are frequently dose-dependent and irreversible, clinicians hesitate to utilize aminoglycosides in their routine practice. 

Furthermore, the high cost of aminoglycosides adds to their restricted utilization and limits market growth. Pharmaceutical companies are aggressively investing in research and development efforts to produce breakthrough formulations and combinations in order to address these difficulties. These efforts attempt to reduce the adverse effects of aminoglycosides while increasing their efficiency, making them more appealing and viable for general usage. 

Aminoglycosides Market Segment Analysis

The global aminoglycosides market is segmented based on product type, route of administration, application, and region.

The Feed Segment is Expected to Hold a Dominant Position in the Global Aminoglycosides Market Over the Forecast Period.

The feed segment is projected to dominate the global aminoglycosides market accounting market share of about 26.7%, owing to the rising prevalence of increased occurrence of gram-positive and gram-negative bacterial infections in ruminant animals and increasing prevalence of animal infectious diseases, thereby making aminoglycosides a popular choice. 

Aminoglycosides are absorbed from the rumen and into the bloodstream when provided in feed. This is a handy and cost-effective method of pharmaceutical administration. The poultry and pig sectors account for the majority of sales of in-feed and in-water aminoglycoside products.  Commonly used aminoglycosides in veterinary medicine include gentamicin, amikacin, streptomycin, and neomycin. 

Streptomycin is an aminoglycoside antibiotic that is commonly used in veterinary medicine in the form of the sulfate salt. It has been used to treat bacterial illnesses in animals such as cattle, pigs, sheep, and poultry. The suggested therapeutic doses are 5 to 10 mg/kg bw/day via parenteral route for 3 to 5 days or 25 to 100 mg/kg bw/day by drinking water for 3 to 5 days. Thus, owing to the above factors and utilizing aminoglycosides by feeding route could inhibit the growth of bacterial infection in animals, thereby driving the segment growth over the forecast period.

Source: DataM Intelligence Analysis (2023)

Aminoglycosides Market Geographical Share

North America Holds a Dominant Position in the Global Aminoglycosides Market.

North America is estimated to hold around 36.9% of the total market share throughout the forecast period. The high prevalence of bacterial infections, rising incidence of antibiotic resistance, strong presence of key players, and increasing geriatric population are expected to drive the aminoglycosides market growth in North America region over the forecast period.

The growing geriatric population in the U.S. is expected to dominate the market, as the elderly population is more vulnerable to bacterial infections in general, and the prevalence of these diseases tends to grow with age. For instance, according to WHO 2022 report, by 2030, one in every six people globally is expected to be 60 or older. This reflects a huge demographic transition, with the population of people aged 60 and up increasing from 1 billion in 2020 to 1.4 billion throughout that time span. 

Furthermore, the worldwide population of persons aged 60 or more is predicted to treble by 2050, reaching 2.1 billion people. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Aminoglycosides Market Companies

The major global players in the market include Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals. Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, and Kremoint Pharma Pvt. Ltd., among others.

COVID-19 Impact on Aminoglycosides Market

The COVID-19 outbreak has had a substantial influence on the global aminoglycosides industry. The pandemic disrupted worldwide supply chains and reduced demand for goods and services in a variety of industries, including the Aminoglycosides industry. One of the most significant effects of COVID-19 on the aminoglycosides market is the disruption of supply chains, which has resulted in a decline in aminoglycoside antibiotic production. 

The pandemic has also increased antibiotic usage, as individuals are becoming more concerned about their health and taking adequate prescriptions to avoid infections and lengthier hospital stays. However, aminoglycosides may have particular benefits in the fight against COVID-19. According to a 2021 paper published by the National Library of Medicine, aminoglycosides have the potential to be SARS-CoV-2 antivirals. In vitro, inhibition of murine hepatitis virus (MHV) was demonstrated by the aminoglycosides hygromycin B (hygB) and neomycin. Others discovered hygB activity against bovine and feline coronaviruses.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine is expected to have a substantial influence on the global aminoglycoside market. Because of the incidence of infectious diseases in war zones, has led to higher pricing, supply chain interruptions, and increased demand for aminoglycosides. These factors are predicted to reduce market demand, raise prices, and disrupt the supply chain, making it difficult for patients to get essential aminoglycoside drugs. Furthermore, the conflict's indirect effects, such as lower economic growth and lower demand for healthcare services, may contribute to the market's pessimistic view. While the full extent of the conflict's impact is unknown, it is clear that the global aminoglycosides industry will be severely impacted.

Key Developments

• In May 2022, Cerament G, a resorbable, gentamicin-eluting ceramic bone graft substitute, has been approved by the Food and Drug Administration (FDA) for use as a bone void filler in skeletally mature patients as an adjunct to systemic antibiotic therapy and surgical debridement in the surgical treatment of osteomyelitis.
• In April 2023, in a Chapter 11 US Bankruptcy Code auction of Achaogen's assets, Cipla USA Inc. acquired the prescription medicine ZEMDRI (Plazomicin) from Achaogen Inc. Cipla USA has purchased ZEMDRI's worldwide rights (except Greater China) as well as its allied assets and minimal liabilities.
• In March 2022, Padagis' AB-rated generic form of Tobradex Ophthalmic Suspension was approved by the US Food and Drug Administration (FDA). The active ingredients in this generic version are the same as those in the original medicine, namely tobramycin and dexamethasone. Tobradex Ophthalmic Suspension is used to treat inflammatory eye disorders that react to steroids when a corticosteroid is required and there is either an existing superficial bacterial ocular infection or a risk of such an infection.

Why Purchase the Report?

• To visualize the global aminoglycosides market segmentation based on the product type, route of administration, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of aminoglycosides market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global aminoglycosides market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies